{"organizations": [], "uuid": "02e0eca21a867dc2bb39e164dfea917a25971bfd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180110.html", "section_title": "Archive News &amp; Video for Wednesday, 10 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-syndax-pharmaceuticals-announces-c/brief-syndax-pharmaceuticals-announces-clinical-collaboration-to-evaluate-entinostat-in-combination-with-anti-pd-l1-cancer-immunotherapy-in-breast-cancer-idUSFWN1P50BX", "country": "US", "domain_rank": 408, "title": "BRIEF-Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-10T20:11:00.000+02:00", "replies_count": 0, "uuid": "02e0eca21a867dc2bb39e164dfea917a25971bfd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-syndax-pharmaceuticals-announces-c/brief-syndax-pharmaceuticals-announces-clinical-collaboration-to-evaluate-entinostat-in-combination-with-anti-pd-l1-cancer-immunotherapy-in-breast-cancer-idUSFWN1P50BX", "ord_in_thread": 0, "title": "BRIEF-Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "syndax pharmaceuticals inc", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "neutral"}, {"name": "tion", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "genentech", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 10 (Reuters) - Syndax Pharmaceuticals Inc:\n* SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER\n* SYNDAX PHARMACEUTICALS INC - NEW CLINICAL COLLABORATION WITH GENENTECH, A MEMBER OF ROCHE GROUP\n* SYNDAX PHARMACEUTICALS - COS WILL EVALUATE COMBINATION OF CO‘S ENTINOSTAT AND GENENTECH‘S ATEZOLIZUMAB\n* SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED.\n* SYNDAX PHARMACEUTICALS INC - GENENTECH WILL BE RESPONSIBLE FOR CONDUCTING TRIAL\n* SYNDAX PHARMACEUTICALS INC - TRIAL WILL BE CONDUCTED AS PART OF MORPHEUS, ROCHE‘S NOVEL CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-10T20:11:00.000+02:00", "crawled": "2018-01-11T12:17:55.002+02:00", "highlightTitle": ""}